Kidney Week 2017

Tolvaptan Improved Hyponatremia in Patient with Melanoma

New Orleans—The 10-year survival rate for patients with metastatic melanoma is <10%. The majority of patients are treated with systemic therapy, and there are associations between immunotherapeutic agents and durable response in some patients. In 1998, the FDA approved high dose interleukin-2 (IL-2) for treatment of metastatic melanoma. Common adverse effects include fever, chills, hypotension, cardiac arrhythmias, oliguria, volume overload, ... Read More »

Rapid Correction of Severe Hyponatremia

New Orleans—In patients with severe hyponatremia, rapid correction of serum sodium can result in serious adverse clinical consequences, including central pontine myelinolysis (CPM). There are few available data on the clinical risk factors associated with rapid correction of hyponatremia and on the incidence of CPM among patients with severe hyponatremia. Jason C. George, MD, and colleagues utilized data on 1352 ... Read More »